Researchers discover brain pattern that could improve mental health disorder diagnosis

December 17, 2020

A pattern in how the brain breaks down tryptophan, a common amino acid consumed through food, was discovered by researchers at The University of Texas Health Science Center at Houston (UTHealth). The finding, which could help physicians more accurately diagnose and treat several major mental health disorders, was recently published in Molecular Psychiatry.

"Tryptophan can be metabolized to either a route where serotonin is produced, or to the kynurenine pathway," said Brisa Fernandes, MD, MSc, PhD, a postdoctoral research fellow with the Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences at McGovern Medical School at UTHealth and co-senior author of the paper. "The research shows that people with mood disorders and schizophrenia not only have decreased levels of tryptophan overall, but the tryptophan they do have is being broken down more often in the kynurenine pathway, shifting away from the production of serotonin, the chemical made from tryptophan that is thought to regulate anxiety and improve mood."

Researchers conducted a systematic review of more than 100 peer-reviewed studies assessing kynurenine metabolites, which are the tryptophan amino acids being broken down in the kynurenine pathway, in people with major depressive disorder, schizophrenia, or bipolar disorder, compared to healthy controls. Within those studies, which included more than 10,000 study participants, they examined the difference in metabolite concentrations between each group.

"We chose these disorders because they share several biological pathways, meaning the same root causes and pathophysiology. We tried to find biomarkers that are common among these disorders, but most importantly, biomarkers that distinguish them. This is essential to help clinicians guide treatment and implement personalized medicine in psychiatry - not the 'one-size-fits-all' approach that is so prevalent today," Fernandes said.

As the tryptophan breaks down in the brain, it can use the kynurenine pathway to turn into quinolinic acid, which is considered neurotoxic, or kynurenic acid, which is considered neuroprotective.

Researchers identified several patterns that occur as tryptophan breaks down that collectively suggest there is a shift from serotonin production to the kynurenine pathway, which could lead to increased neurotoxicity from the quinolinic acid.

"This can help us to develop new tests for diagnosing these disorders and, more importantly, of discovering and selecting new treatments for people with mood disorders and schizophrenia that will be more personalized," Fernandes said.

"The major challenge that we have in psychiatry is having biomarkers to differentiate one diagnostic from the other, as our diagnoses are 100% clinical. This is the type of research we need to identify those biomarkers, and the next step for us now is to see if we can validate these findings in our patients," said João de Quevedo, MD, PhD, professor of psychiatry and behavioral sciences and co-author of the study.

"This is important research that hopefully will lead to a better understanding of mechanisms involved in major mental illnesses, as well as a higher level of personalization in treatments so we can best match patients to a treatment plan we know will help them," said Jair Soares, MD, PhD, the Pat R. Rutherford, Jr. Chair in Psychiatry in the Faillace Department of Psychiatry and Behavioral Sciences and co-senior author. Soares and de Quevedo see patients at UT Physicians, the clinical practice of McGovern Medical School.
Co-first authors include Wolfgang Marx, PhD, a postdoctoral research fellow with Deakin University in Australia and Amelia McGuinness, a PhD student at Deakin University.

Media inquiries: 713-500-3030

University of Texas Health Science Center at Houston

Related Schizophrenia Articles from Brightsurf:

Schizophrenia: When the thalamus misleads the ear
Scientists at the University of Geneva (UNIGE) and the Synapsy National Centre of Competence in Research (NCCR) have succeeded in linking the onset of auditory hallucinations - one of the most common symptoms of schizophrenia - with the abnormal development of certain substructures of a region deep in the brain called the thalamus.

Unlocking schizophrenia
New research, led by Prof. LIU Bing and Prof. JIANG Tianzi from the Institute of Automation of the Chinese Academy of Sciences and their collaborators have recently developed a novel imaging marker that may help in the personalized medicine of psychiatric disorders.

Researchers discover second type of schizophrenia
In a study of more than 300 patients from three continents, over one third had brains that looked similar to healthy people.

New clues into the genetic origins of schizophrenia
The first genetic analysis of schizophrenia in an ancestral African population, the South African Xhosa, appears in the Jan.

Dietary supplement may help with schizophrenia
A dietary supplement, sarcosine, may help with schizophrenia as part of a holistic approach complementing antipsychotic medication, according to a UCL researcher.

Schizophrenia: Adolescence is the game-changer
Schizophrenia may be related to the deletion syndrome. However, not everyone who has the syndrome necessarily develops psychotic symptoms.

Study suggests overdiagnosis of schizophrenia
In a small study of patients referred to the Johns Hopkins Early Psychosis Intervention Clinic (EPIC), Johns Hopkins Medicine researchers report that about half the people referred to the clinic with a schizophrenia diagnosis didn't actually have schizophrenia.

The ways of wisdom in schizophrenia
Researchers at UC San Diego School of Medicine report that persons with schizophrenia scored lower on a wisdom assessment than non-psychiatric comparison participants, but that there was considerable variability in levels of wisdom, and those with higher scores displayed fewer psychotic symptoms.

Recognizing the uniqueness of different individuals with schizophrenia
Individuals diagnosed with schizophrenia differ greatly from one another. Researchers from Radboud university medical center, along with colleagues from England and Norway, have demonstrated that very few identical brain differences are shared amongst different patients.

Resynchronizing neurons to erase schizophrenia
Today, a decisive step in understanding schizophrenia has been taken.

Read More: Schizophrenia News and Schizophrenia Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to